Market cap
$258 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -3.82 | -20.94 | -39.51 | -27.04 | -218.05 |
| Net Profit | -3.56 | -20.10 | -38.39 | -33.61 | -222.38 |
| EPS | -1.20 | -15.41 | -23.75 | 10.81 | -2.98 |
| Book Value | -- | -- | -59.52 | -41.60 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-24 | Dec-23 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -4,621.96 | -109,040.50 | -- | -- | -- |
| Return on equity
| -71.76 | -69.38 | -186.26 | -102.90 | -54.94 |
| Return on Capital
| -56.83 | -60.09 | -- | -69.93 | -45.56 |
| Return on Assets
| -51.55 | -48.91 | -65.21 | -62.97 | -41.86 |
| Debt to Equity (x)
| -- | -- | 0.65 | 0.81 | 0.33 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
-69.93
|
-45.56
|
-54.99
|
-41.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-186.26
Lower than Peers by 145.93
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-186.26
|
-102.90
|
-54.94
|
-57.44
|
-42.20
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-65.21
Lower than Peers by 33.97
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-65.21
|
-62.97
|
-41.86
|
-49.82
|
-38.52
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
--
|
--
|
-4,621.96
|
-313,405.56
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
EBIT Growth
-39.51
Lower than Peers by 38.49
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-39.51
|
-42.22
|
-10.15
|
-20.43
|
0.03
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-38.39
Lower than Peers by 30.86
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-38.39
|
-43.35
|
-8.74
|
-16.01
|
-1.03
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-23.75
Lower than Peers by 37.98
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-23.75
|
-0.41
|
0.28
|
0.33
|
0.23
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-74.29
Lower than Peers by 64.15
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-74.29
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.65
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
0.65
|
0.81
|
0.33
|
0.06
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.83
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
0.83
|
0.28
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.19
Lower than Peers by 3.62
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
2.19
|
3.56
|
13.36
|
8.93
|
9.92
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.19
Lower than Peers by 3.51
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
2.19
|
--
|
--
|
8.94
|
9.92
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-17.92
Lower than Peers by 15.84
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-17.92
|
-19.36
|
-22.70
|
-42.55
|
-2,592.00
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
--
|
-32.46
|
-27.46
|
-2,155.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
--
|
523.60
|
766.19
|
948.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
-1.71
|
-3.70
|
-0.65
|
-2.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
8.12
Higher than Peers by 2.79
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
8.12
|
3.01
|
1.87
|
0.36
|
1.48
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-4.25
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
-4.25
|
-1.04
|
-1.62
|
1.15
|
-0.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
258
Higher than Peers by 117
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
258
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|